Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/29/2022* -- Results Q2 2022 -- -1.57 --
07/29/2022* 08:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -1.79 -1.76 -1.52%
05/05/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 -1.77 -1.57 -12.56%
02/24/2022 08:00 EST Earnings Call Q4 2021 -- -- --
11/03/2021 -- Results Q3 2021 -1.51 -1.57 3.55%
11/03/2021 08:00 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/29/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/05/2022
Beat/Miss Upgrade
Return Since -8.26%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
URL https://www.agios.com
Investor Relations URL https://investor.agios.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release May. 05, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-42.06%
-35.72%
37.00%
-19.35%
3.56%
-9.26%
-24.14%
-35.81%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
59.29%
-12.42%
222.6%
-41.84%
-24.64%
19.84%
-50.83%
-23.53%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
4.69%
-13.79%
-67.42%
0.22%
-78.75%
511.8%
31.15%
540.8%
-42.45%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
17.76%
As of May 20, 2022.

Profile

Edit
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
URL https://www.agios.com
Investor Relations URL https://investor.agios.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release May. 05, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
F000016ZDA 303.00 USD 3.03%
FBT 36.25M USD 2.84%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter AGIO Tweets